GlobalData on MSN1mon
Supernus wins FDA approval for Parkinson’s pump on fourth trySupernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...
Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...
President and CEO of Supernus. “In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025 ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
About Supernus Pharmaceuticals ... to commercialize its products and the products of its subsidiaries including ONAPGO; the Company’s ability to enter into future collaborations with ...
Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA ...
President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further ...
President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback